We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multi Sample Osmometer Improves Testing Efficiency

By LabMedica International staff writers
Posted on 03 Aug 2016
Image: The OsmoPRO multi-sample osmometer for automated testing (Photo courtesy of Advanced Instruments).
Image: The OsmoPRO multi-sample osmometer for automated testing (Photo courtesy of Advanced Instruments).
A novel 20-position micro sample osmometer improves laboratory efficiency, productivity, and workflow by reducing sample turn-around time.

The OsmoPRO Multi-Sample Osmometer for automated osmolality testing is designed to analyze a variety of complex aqueous mixtures, including blood, serum, plasma, urine, cell culture media, drug formulations, and biological cell therapies, using a small, 20 μL sample size. Samples can be analyzed one at a time, or batch processed depending on workflow demands. Timesaving features include an intuitive touch screen, automated processing, and the ability to run unattended. The device also uses the freezing point depression method to deliver results in just two minutes.

The OsmoPRO can be used in a variety of laboratory applications including clinical diagnostics, formulation development, bioprocess monitoring and process control, industrial, environmental, and finished product quality control. An integrated barcode scanner provides positive sample identification to reduce transcription errors, with data management and transfer handled via the on-board printer or by exporting the data using an ethernet connection and multiple USB ports. The OsmoPRO multi-sample osmometer, a product of Advanced Instruments (Norwood, MA, USA), will be presented at AACC 2016.

“OsmoPRO incorporates more than 60 years of applied technology and expertise from Advanced Instruments, the industry leader in the field of osmometry,” said Peter Costas, vice president of sales and marketing at Advanced Instruments. “OsmoPRO replaces the Advanced Model 2020 osmometer, which has been an extremely popular and reliable osmometer used in thousands of laboratories worldwide, and represents Advanced Instruments commitment to quality and innovation in the field of osmometry”.

Osmometers are used for measuring the osmotic strength of a solution, colloid, or compound, or determining the molecular weight of unknown compounds and polymers. Several techniques can be used, including vapor pressure depression to determine the concentration of osmotically active particles; determining the osmotic pressure of a solution separated from pure solvent by a semipermeable membrane; and freezing point depression to determine osmotically active compounds in a solution.

The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is an international scientific/medical society of over 8,000 clinical laboratory professionals, physicians, research scientists and more. The AACC annual meeting, which will be held from July 31st to August 4th at the Pennsylvania Convention Center in Philadelphia (USA), features five days of educational sessions on scientific, clinical, technical and management challenges facing laboratory professionals, as well as the world’s largest Clinical Lab Expo.

Related Links:
Advanced Instruments
American Association for Clinical Chemistry
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Nucleic Acid Purification Instrument
QIAsymphony Connect

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more